Exosome Analysis in Prostate Cancer: How They Can Improve Biomarkers’ Performance
-
Published:2023-07-21
Issue:7
Volume:45
Page:6085-6096
-
ISSN:1467-3045
-
Container-title:Current Issues in Molecular Biology
-
language:en
-
Short-container-title:CIMB
Author:
Salciccia Stefano1ORCID, Frisenda Marco1ORCID, Bevilacqua Giulio1, Gobbi Luca1, Bucca Bruno1, Moriconi Martina1, Viscuso Pietro1, Gentilucci Alessandro1, Mariotti Gianna1, Cattarino Susanna1, Forte Flavio2, Fais Stefano3, Logozzi Mariantonia3, Sciarra Beatrice4, Sciarra Alessandro1ORCID
Affiliation:
1. Department Materno Infantile Scienze Urologiche, University Sapienza, Viale Policlinico 155, 00161 Rome, Italy 2. Figliesancamillo Hospital, 00198 Rome, Italy 3. Istituto Superiore di Sanita, Viale Regina Elena, 00161 Rome, Italy 4. Department of Chemistry, University Sapienza, Viale Universita, 00161 Rome, Italy
Abstract
Exosomes are extracellular nanovesicles (EV), that is, carriers of different biomolecules such as lipids, proteins, nucleic acids. Their composition and the fact that their release dramatically increases in cases of tumorigenesis open up different scenarios on their possible application to research into new biomarkers. The first purpose of the present review was to specifically analyze and compare different methodologies available for the use of exosomes in prostate cancer (PC). The most widely applied methodologies include ultracentrifugation techniques, size-based techniques, immunoaffinity capture-based techniques (mainly ELISA), and precipitation. To optimize the acquisition of exosomes from the reference sample, more techniques can be applied in sequence for a single extraction, thereby determining an increase in labor time and costs. The second purpose was to describe clinical results obtained with the analysis of PSA-expressing exosomes in PC; this provides an incredibly accurate method of discriminating between healthy patients and those with prostate disease. Specifically, the IC-ELISA alone method achieved 98.57% sensitivity and 80.28% specificity in discriminating prostate cancer (PC) from benign prostatic hyperplasia (BPH). An immunocapture-based ELISA assay was performed to quantify and characterize carbonic anhydrase (CA) IX expression in exosomes. The results revealed that CA IX positive exosomes were 25-fold higher in plasma samples from PC patients than in those from healthy controls. The analysis of PC-linked exosomes represents a promising diagnostic model that can effectively distinguish patients with PC from those with non-malignant prostatic disease. However, the use of exosome analysis in clinical practice is currently limited by several issues, including a lack of standardization in the analytical process and high costs, which are still too high for large-scale use.
Subject
Microbiology (medical),Molecular Biology,General Medicine,Microbiology
Reference35 articles.
1. Active surveillance for prostate cancer: A systematic review of the literature;Albertsen;Eur. Urol.,2012 2. Salciccia, S., Capriotti, A.L., Laganà, A., Fais, S., Logozzi, M., De Berardinis, E., and Sciarra, A. (2021). Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes. Int. J. Mol. Sci., 22. 3. Exosomes: The future of biomarkers in medicine;Properzi;Biomark. Med.,2013 4. REporting recommendations for tumour MARKer prognostic studies (REMARK);McShane;Br. J. Cancer,2005 5. Approaches to urinary detection of prostate cancer;Eskra;Prostate Cancer Prostatic Dis.,2019
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|